COMMUNIQUÉS West-GlobeNewswire
-
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
13/07/2026 -
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
13/07/2026 -
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
13/07/2026 -
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
13/07/2026 -
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
13/07/2026 -
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
13/07/2026 -
VitalHub Announces Acquisition of Buddy Healthcare
13/07/2026 -
NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
13/07/2026 -
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
13/07/2026 -
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
13/07/2026 -
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
13/07/2026 -
BrewDog Waterloo to Host England's Biggest Pub Watch Party for Blockbuster Semifinal
13/07/2026 -
Acentra Health Appoints Michael Kingston as Chief Digital & Information Officer to Lead Technology and AI Innovation
13/07/2026 -
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
13/07/2026 -
Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil
13/07/2026 -
Omada Health to Participate in Canaccord Genuity’s 46th Annual Growth Conference
13/07/2026 -
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
13/07/2026 -
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
13/07/2026 -
Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call
13/07/2026
Pages